Mitochon Technologies works on the pharmacological exploitation of the natural defense mechanism of our cells. The lead compound of the development, BGP-15 targets the cellular stress responses, including the heat shock protein and mitochondrial stress responses. Due to the ubiquitous nature of the targeted mechanism BGP-15 resulted in therapeutic effects in wide variety of diseases, including serious diseases without efficient treatment.